Pfizer's Trading Volume Drops 22.56% to $10.94 Billion Ranking 56th Amid FDA Cancer Drug Review

On May 7, 2025, Pfizer's trading volume reached $10.94 billion, a 22.56% decrease from the previous day, ranking 56th in the day's stock market. Pfizer (PFE) fell 0.39%, marking its third consecutive day of decline, with a total drop of 5.83% over the past three days.

Pfizer Inc. is currently awaiting the FDA panel review of its cancer drug, which has been a significant focus for the company. This review is crucial as it could potentially impact the company's future revenue streams and market position. The outcome of this review will be closely watched by investors and analysts alike, as it could influence Pfizer's stock performance in the coming months.